Cargando…
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of com...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613187/ https://www.ncbi.nlm.nih.gov/pubmed/37776480 http://dx.doi.org/10.1007/s13555-023-01040-9 |
_version_ | 1785128775302774784 |
---|---|
author | Casale, Thomas B. Gimenez-Arnau, Ana Maria Bernstein, Jonathan A. Holden, Michael Zuberbier, Torsten Maurer, Marcus |
author_facet | Casale, Thomas B. Gimenez-Arnau, Ana Maria Bernstein, Jonathan A. Holden, Michael Zuberbier, Torsten Maurer, Marcus |
author_sort | Casale, Thomas B. |
collection | PubMed |
description | Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients. |
format | Online Article Text |
id | pubmed-10613187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-106131872023-10-30 Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status Casale, Thomas B. Gimenez-Arnau, Ana Maria Bernstein, Jonathan A. Holden, Michael Zuberbier, Torsten Maurer, Marcus Dermatol Ther (Heidelb) Review Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients. Springer Healthcare 2023-09-30 /pmc/articles/PMC10613187/ /pubmed/37776480 http://dx.doi.org/10.1007/s13555-023-01040-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Casale, Thomas B. Gimenez-Arnau, Ana Maria Bernstein, Jonathan A. Holden, Michael Zuberbier, Torsten Maurer, Marcus Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title | Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title_full | Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title_fullStr | Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title_full_unstemmed | Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title_short | Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status |
title_sort | omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613187/ https://www.ncbi.nlm.nih.gov/pubmed/37776480 http://dx.doi.org/10.1007/s13555-023-01040-9 |
work_keys_str_mv | AT casalethomasb omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus AT gimenezarnauanamaria omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus AT bernsteinjonathana omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus AT holdenmichael omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus AT zuberbiertorsten omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus AT maurermarcus omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus |